Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations-Reference-Cited by-同舟云学术

Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations

Published:2015-01 Issue:1 Volume:4 Page:12-27
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Mould DR¹,Walz A‐C²,Lave T²,Gibbs JP³,Frame B¹

Affiliation:

1. Projections ResearchPhoenixville Pennsylvania USA

2. Roche Pharma Research and Early Development, Modeling & Simulation, Pharmaceutical SciencesRoche Innovation Center BaselF. Hoffmann‐La RocheBasel Switzerland

3. AmgenThousand Oaks California USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.16

Reference100 articles.

1. Optimizing oncology therapeutics through quantitative clinical pharmacology: challenges and opportunities;Venkatakrishnan K.;Clin. Pharmacol. Ther.

2. Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

3. US Department of Health and Human Services Food and Drug Administration.Critical Path Opportunities. (2006). Accessed 5 July2013.

4. Model-based Drug Development

5. RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox—Point

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach;CPT: Pharmacometrics & Systems Pharmacology;2024-07-23

2. Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer;Clinical Pharmacology & Therapeutics;2023-10-12

3. Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2;Pharmaceutical Research;2023-10-05

4. Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology;CPT: Pharmacometrics & Systems Pharmacology;2023-09-28

5. In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III;International Journal of Molecular Sciences;2023-01-23